Co-Diagnostics, Inc.

CODX Healthcare Medical Devices

Co-Diagnostics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $622,500.00, down 84.1% from fiscal 2024. In the quarter to June 2026, revenue grew 1.96%, EPS grew 78.9% and free cash flow grew 17.5%, each against the same quarter a year earlier.

0.65 0.07 −9.72%
Market cap
$5.3M
P/E
0.0×
Fwd P/E
−0.4×
Dividend yield
—
F-score
2/9
Altman Z
−9.74
Beneish M
2.24
Dividend safety
n/a

Co-Diagnostics, Inc. (CODX) P/E ratio

Alert me on P/E ratio

Co-Diagnostics, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 147× (August 2020) — the current reading is the lowest in ten years.

P/E ratio, daily

Embed this chart

Annual newest first

Period P/E ratio Change
FY2025 0.0× —
FY2024 0.0× —
FY2023 0.0× —
FY2022 0.0× —
FY2021 7.0× 7.28%
FY2020 6.5× —
FY2019 0.0× —
FY2018 0.0× —
FY2017 0.0× —

Quarterly newest first

Period P/E ratio Change
Jun 2026 0.0× —
Mar 2026 0.0× —
Dec 2025 0.0× —
Sep 2025 0.0× —
33 more quarters

Against its own ten years

Low 0.0× High 147×
Ten-year median 0.0×
Current reading's percentile 73

P/E ratio against peers

What P/E ratio is

Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.

Stock Price ÷ EPS (Basic) (TTM)

The full definition of P/E ratio →

More on CODX